Celebrating 10 Years of Trusted News Discovery
One News Page
ValiRx News 

Hardman & Co Research: ValiRx (VAL): VAL401 Phase II trial completed

Hardman & Co Research 01-Nov-2018 / 07:15 GMT/BST -------------------- *Hardman & Co: VAL401 Phase II trial completed* ValiRx (VAL) is a clinical-stage biopharmaceutical company..
EQS Group - Published

ValiRx granted crucial EU patent for VAL201

(WebFG News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the European Union patent and trademark office has granted EU Patent Application 08717866.1 - Anti-Androgen Pe... - Published

ValiRx soars on anti-cancer compound's successful study

Clinical stage biotechnology company ValiRx has seen positive results from recent studies into the effectiveness of its VAL101 compound's ability to induce cancer cells to kill themselves off. Vali... - Published

ValiRx narrows losses after cutting R&D costs

AIM-quoted life science company ValiRx narrowed losses in its most recent trading year after making "important strides" in growing its internal research and development capabilities. ValiRx reduced... - Published

Global Endometriosis Business Report 2018: Overview, Treatment, Innovations & Approvals, Recent Industry Activity & Focus on Select Players

Dublin, March 22, 2018 (GLOBE NEWSWIRE) -- The "Endometriosis - Global Strategic Business Report" report has been added to *'s* offering. The report provides separate..
GlobeNewswire - Published

ValiRx gets US patent for VAL201 compound

Clinical stage biotechnology company ValiRx announced on Tuesday that the US patent and trademark office has granted the patent application 14/575065 (Anti-Androgen Peptides and Uses Thereof in Can... - Published

ValiRX awarded regulatory approval to fast track prostate cancer study

Biopharmaceutical company ValiRX was said to be entering a "new and exciting phase" after it was granted approval to expand and accelerate its early-stage cancer study. ValiRX was given permission ... - Published

Valirx making progress on several fronts

Life sciences group ValiRx Plc (LON:VAL) is making good progress as it continues to run its lead candidate through the clinical trial process to treat prostate cancer, and  where results so far have..
Proactive Investors - Published

Shares in drug developers Sareum and Valirx soar but oilers endure another bad week

shares in drug developers sareum and valirx soar but oilers endure another bad week
In the last three months the AIM All Share has risen a creditable 15 per cent, outperforming the FTSE 100 (up 9.5 per cent). Sareum's shares have sky-rocketed more than 80 per cent.
MailOnline - Published Also reported by •

Beaufort Securities Breakfast Alert: Herenica Resources, Keras Resources, Northcote Energy, Stellar Diamonds, ValiRx, BAE Systems, British American Tobacco, BT, Diageo, Domino's Pizza, Merlin Entertainments, Sky

(MENAFN - ProactiveInvestors - UK) Beaufort Securities, 08:32 Markets Europe The FTSE-100 finished yesterday's session 0.44% lower at 6,721.06, whilst the FTSE AIM All-Share ... - Published

Risers & fallers: Baron Oil, Blenheim Natural Resources, Bluebird Merchant Ventures, Brave Bison, Harvest Minerals, ValiRx

Below are some of the main news-driven share price changes at 9.15am. RISERS Baron Oil PLC (LON:BOIL), up 19%. The outgoing President of the Republic of Peru has signed the supreme decree with respect..
Proactive Investors - Published

Proactive news highlights: Bacanora, Leni Gas Cuba, Metal Tiger, Westminster Group and more...

Leni Gas Cuba Limited (ISDX:CUBA) announced that shareholders had unanimously approved the previously-announced reverse take-over of Knowlton. Shareholders also approved a change of corporate name to..
Proactive Investors - Published

ValiRx PLC readies for phase II clinical trial of lead cancer drug

ValiRx Plc (LON:VAL) said manufacturing of VAL401 had begun ahead of a phase II clinical trial of the drug in patients with advanced lung cancer. The study will assess efficacy, safety and tolerability..
Proactive Investors - Published

ValiRx joint venture awarded second US patent

Cancer drug developer ValiRx Plc’s (LON:VAL) joint venture Valiseek has received a US patent for its lead compound VAL401 as a possible treatment for adenocarcinoma cancers. The drug is targeting..
Proactive Investors - Published

ValiRx PLC to present at leading US cancer conference

Shares in ValiRx PLC (LON:VAL) rose 2% after the life sciences specialist said it would be presenting research data at a leading oncology get-together in the US next month. The American Association for..
Proactive Investors - Published

Risers and Fallers: Gulfsands PLC, NetPlay TV, ValiRx PLC...

Major share price movers in London at 9.45am RISERS Gulfsands Petroleum PLC (LON;GPX) up 52% to 7.55p.  Further recovery after results on Friday. Syrian operations suspended but company remains..
Proactive Investors - Published

ValiRx PLC targets US institutions with new appointment

ValiRx Plc (LON:VAL) has appointed a specialist investor relations firm to build its recognition among academic, clinical, and business leaders in the US.  Burns McClellan has already carried out an..
Proactive Investors - Published

ValiRx trial group receives cancer treatment with no adverse effects

ValiRx (LON:VAL) said a further group of patients receiving VAL201 have completed the clinical trial dosing sequence with no significant adverse effects. VAL201 is being developed to treat..
Proactive Investors - Published

Small cap highlights: Europa, Providence, Rockhopper, DP Poland, 32 Red, Tern, ValiRX, and more

Europa Oil & Gas (LON:EOG) shot up by about a third in Friday’s early deals as a new licensing round offshore Ireland showed the small cap oiler is punching above its weight. The AIM-quoted explorer..
Proactive Investors - Published

You Might Like

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest